Cardiff Oncology just settled yesterday + HC Wainwright upgraded CRDF to BUY with a PT of $9.
I got into this end of July at 81 cents - 5 days ago it was $1.21 - yesterday $1.31 - and pre-market it's taking off. I got in after seeing a very large $1M insider purchase (Gary Pace) recently. His cost average is roughly a buck and half-ish.
The settlement yesterday with NMS (Nerviano) secures exclusive rights and extends royalties for onvansertib, which is advancing to a global Phase 3 trial in first-line RAS mutated metastatic colorectal cancer. The trial targets accelerated approval based on ORR, with robust financial and pipeline expansion plans.
The litigation about inventorship was the only thing that was holding this back. Now it's full speed ahead.
If you haven't added this to your watchlist - now is the time.
They are targeting a huge, underserved market... and recent readouts suggest their drug drastically beats standard-of-care and they call it "onvansertib".
They just completed a successful End of Ph 2 meeting with FDA. Phase 3 is targeted for Q1 2027.
Cash Balance: \~$34.5M at Q2 2026, plus an extra $10M raised via registered direct offering in July 2026.
Analyst PT last week was between $4.18 and $7.50. Today it has a PT of $9.
Anyways, worth a watchlist add.
